DAE HWA Pharmaceutical Co. Ltd (067080) — Cash Flow Quality Index
DAE HWA Pharmaceutical Co. Ltd (067080) has a Cash Flow Quality Index of 0.65x as of December 2025. Operating cash flow of ₩2.06 Billion is below net income of ₩3.18 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore DAE HWA Pharmaceutical Co. Ltd cash conversion from operations to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
DAE HWA Pharmaceutical Co. Ltd Cash Flow Quality Index (2011–2025)
Historical Cash Flow Quality Index for DAE HWA Pharmaceutical Co. Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 067080 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Year-by-year earnings quality comparison for DAE HWA Pharmaceutical Co. Ltd. For live market cap and the full company financial profile, see DAE HWA Pharmaceutical Co. Ltd (067080) market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 3.28x | ₩5.43 Billion | ₩1.65 Billion | ▼ -55.5% |
| 2024 | 7.38x | ₩6.13 Billion | ₩829.83 Million | ▲ +12.0% |
| 2022 | 6.59x | ₩8.05 Billion | ₩1.22 Billion | ▲ +23.8% |
| 2021 | 5.32x | ₩10.45 Billion | ₩1.96 Billion | ▲ +136721.3% |
| 2019 | 0.00x | ₩-41.07 Million | ₩10.54 Billion | ▼ -100.2% |
| 2018 | 1.58x | ₩10.49 Billion | ₩6.65 Billion | ▲ +82.4% |
| 2017 | 0.86x | ₩10.94 Billion | ₩12.65 Billion | ▼ -63.3% |
| 2016 | 2.36x | ₩8.79 Billion | ₩3.73 Billion | ▲ +298.6% |
| 2015 | 0.59x | ₩2.43 Billion | ₩4.11 Billion | ▼ -92.7% |
| 2013 | 8.10x | ₩13.57 Billion | ₩1.68 Billion | ▲ +341.9% |
| 2012 | 1.83x | ₩5.77 Billion | ₩3.15 Billion | ▲ +100.9% |
| 2011 | 0.91x | ₩3.43 Billion | ₩3.76 Billion | — |